Last reviewed · How we verify
Abrupt cessation of semaglutide
Abrupt cessation of semaglutide is a GLP-1 receptor agonist Small molecule drug developed by Mount Sinai Hospital, Canada. It is currently in Phase 3 development for Type 2 diabetes mellitus, Obesity or weight management.
Abrupt cessation of semaglutide involves the sudden discontinuation of a GLP-1 receptor agonist, which may result in rapid changes in glucose metabolism and metabolic rebound effects.
Abrupt cessation of semaglutide involves the sudden discontinuation of a GLP-1 receptor agonist, which may result in rapid changes in glucose metabolism and metabolic rebound effects. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | Abrupt cessation of semaglutide |
|---|---|
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon release in response to elevated blood glucose. Upon abrupt cessation, patients may experience rapid loss of these glycemic control benefits, potentially leading to hyperglycemia rebound, weight regain, and metabolic dysregulation. This study likely investigates the clinical consequences and optimal management strategies for discontinuing semaglutide therapy.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Hyperglycemia rebound
- Weight regain
- Loss of glycemic control
- Gastrointestinal symptom resolution
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abrupt cessation of semaglutide CI brief — competitive landscape report
- Abrupt cessation of semaglutide updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI
Frequently asked questions about Abrupt cessation of semaglutide
What is Abrupt cessation of semaglutide?
How does Abrupt cessation of semaglutide work?
What is Abrupt cessation of semaglutide used for?
Who makes Abrupt cessation of semaglutide?
What drug class is Abrupt cessation of semaglutide in?
What development phase is Abrupt cessation of semaglutide in?
What are the side effects of Abrupt cessation of semaglutide?
What does Abrupt cessation of semaglutide target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Mount Sinai Hospital, Canada — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Obesity or weight management
- Compare: Abrupt cessation of semaglutide vs similar drugs
- Pricing: Abrupt cessation of semaglutide cost, discount & access